Description in a few words:
Sanofi Turkey has been serving public health for over 60 years with more than 1,800 employees, offering a broad range of products including: innovative therapeutic solutions, biotechnological pharmaceuticals, vaccines and consumer healthcare products, adding value to local economy and development. Sanofi Turkey includes: Sanofi in innovative pharmaceuticals and branded generics; Sanofi Pasteur fully focused on vaccines; Sanofi Genzyme in rare diseases, oncology, MS and immunology and Consumer Healthcare Unit. Sanofi Turkey offers solutions in 16 main therapeutic areas with almost 275 products.
Sanofi Turkey’s manufacturing site is located at Lüleburgaz, İstanbul, and features state-of-the-art equipment and the latest innovations, producing the highest quality pharmaceuticals.
Cem Öztürk, Country Chair
“Sanofi has a strong footprint in Turkey with an investment of approximately US$1 billion in its Lüleburgaz manufacturing plant, its wide portfolio of innovative medicines and its continuous investments in R&D and clinical trials. Sanofi is ranked as the third largest exporter of pharmaceuticals in Turkey, which account to €35 to €40 million a year in value.”
Main product categories or therapies of focus:
Solid, liquid and sterile pharma products
Number of APIs produced:
No API production
Primary packaging production:
Primary packaging production is for all solid, liquid and sterile product manufacturing
For all solid, liquid and sterile product manufacturing
Total number of delivered boxes/year:
313 million boxes of year (2019)
Sanofi is investing and focusing in these research areas to find innovative solutions for unmet needs: Diabetes & Cardiovascular Diseases, Rare and Neurologic Diseases, Vaccines, Oncology, Immunology & Inflammation Diseases and Rare Blood Disorders.
13% of total production
49 countries including Germany, UK, Japan, France, Australia and Iraq
In More Depth
More than 1,850
21 GMP certificates
1.653 Million TL
Sanofi Turkey has the leading manufacturing facility in Turkey in terms of its production capacity. The manufacturing site manufactures 14% of Turkey’s total pharma production by itself.